To include your compound in the COVID-19 Resource Center, submit it here.
Top-line data from the open-label, U.S. Phase III NEO3-09 trial in over 150 patients showed that Lymphoseek
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury